Richtlijn 'Antistolling bij tandheelkundige ingrepen' - PAOT

Richtlijn ‘Antistolling bij tandheelkundige ingrepen’Inhoudsopgave1. Achtergrondinformatie .............................................................................................. 31.1 VOORWOORD ............................................................................................................................ 31.2 (PATHO)FYSIOLOGIE VAN STOLLING ............................................................................................... 31.2.1. Trombocytenaggregatieremmers ...................................................................................... 51.2.2. Coumarinederivaten .......................................................................................................... 61.3 EPIDEMIOLOGIE .......................................................................................................................... 71.4 DOELGROEP ............................................................................................................................... 71.5 SAMENSTELLING EN WERKWIJZE WERKGROEP .................................................................................. 71.6 JURIDISCHE BETEKENIS VAN DE RICHTLIJN ........................................................................................ 82. De vraagstelling ......................................................................................................... 93. Deelvraag coumarinederivaten ................................................................................ 113.1 DE WERKING EN INDICATIE VAN COUMARINEDERIVATEN .................................................................. 113.2 ANTIBIOTICA ............................................................................................................................ 133.3 METHODEN ............................................................................................................................. 153.4 RESULTATEN ............................................................................................................................ 173.5 CONCLUSIES ............................................................................................................................ 204. Deelvraag acetylsalicylzuur ...................................................................................... 214.1 DE WERKING EN INDICATIE VAN ACETYLSALICYLZUUR ...................................................................... 214.2 BLOEDINGEN EN TANDHEELKUNDIGE BEHANDELINGEN .................................................................... 224.3 SYSTEMATIC REVIEW EN META-ANALYSE ....................................................................................... 224.4 INTERACTIES ............................................................................................................................ 254.5 COUPEREN VAN BLOEDINGEN ..................................................................................................... 264.6 SYNTHESE EN ZOEKSTRATEGIE ..................................................................................................... 264.7 CONCLUSIE .............................................................................................................................. 295. Deelvraag dipyridamol en acetylsalicylzuur .............................................................. 305.1 DE WERKING VAN DIPYRIDAMOL.................................................................................................. 305.2 INDICATIE ................................................................................................................................ 305.3 INTERACTIES MET ANDERE MEDICIJNEN ......................................................................................... 315.4 BLOEDINGEN EN TANDHEELKUNDIGE BEHANDELINGEN .................................................................... 326. Deelvraag clopidogrel .............................................................................................. 336.1 WERKING ................................................................................................................................ 336.2 INDICATIES .............................................................................................................................. 336.3 BELANGRIJKE INTERACTIES .......................................................................................................... 34- 1 -